Ethionamide
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ethionamide (ETA or ETH) is an antibiotic used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, to treat active multidrug-resistant tuberculosis. It is no longer recommended for leprosy. It is taken by mouth. Ethionamide has a high rate of side effects. Common side effects include nausea, diarrhea, abdominal pain, and loss of appetite. Serious side effects may include liver inflammation and depression. It should not be used in people with significant liver problems. Use in pregnancy is not recommended as safety is unclear. Ethionamide is in the thioamides family of medications. It is believed to work by interfering with the use of mycolic acid. Ethionamide was discovered in 1956 and approved for medical use in the United States in 1965. It is on the World Health Organization's List of Essential Medicines.
Ethionamide (ETA or ETH) is an antibiotic used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, to treat active multidrug-resistant tuberculosis. It is no longer recommended for leprosy. It is taken by mouth. Ethionamide has a high rate of side effects. Common side effects include nausea, diarrhea, abdominal pain, and loss of appetite. Serious side effects may include liver inflammation and depression. It should not be used in people with significant liver problems. Use in pregnancy is not recommended as safety is unclear. Ethionamide is in the thioamides family of medications. It is believed to work by interfering with the use of mycolic acid. Ethionamide was discovered in 1956 and approved for medical use in the United States in 1965. It is on the World Health Organization's List of Essential Medicines.
Medical uses
Ethionamide is used in combination with other antituberculosis agents as part of a second-line regimen for active tuberculosis. The antimicrobial spectrum of ethionamide includes M. tuberculosis, M. bovis and M. smegmatis. It also is used rarely against infections with M. leprae and other nontuberculous mycobacteria such as M. avium and M. kansasii. While working in a similar manner to isoniazid, cross resistance is only seen in 13% of strains, since they are both prodrugs but activated by different pathways.
Adverse effects
Ethionamide frequently causes gastrointestinal distress with nausea and vomiting which can lead patients to stop taking it. This can sometimes be improved by taking it with food.
Pharmacology
Other names
1314 2-ethylisothionicotinamide amidazine thioamide iridocin It is sold under the brand name Trecator by Wyeth Pharmaceuticals which was purchased by Pfizer in 2009.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372674176 under CC BY-SA 4.0; modifications have been made.